Modulation of endogenous AICAR levels for the treatment of diabetes and obesity
AssigneeCytRx Corporation
InventorsKaren Bulock, Mark Tepper, John Zhang, Roustem Nabioullin
Life of this patent
Estimating the term…
Loading patent…
AssigneeCytRx Corporation
InventorsKaren Bulock, Mark Tepper, John Zhang, Roustem Nabioullin
Estimating the term…
The invention relates to methods for treating type 2 diabetes, obesity, metabolic syndrome and conditions associated with these by administering an AICAR-monophosphate (AICAR-MP) enhancing agent that increases endogenous AICAR-MP levels in a cell. Inhibition of AICAR-formyltransferase activity (AICARFT) in a cell that regulates metabolic activity (such as fat, liver, muscle, pancreatic beta or certain brain cells) increases AICAR-monophosphate levels which in turn results in activation of the AMP-kinase (AMPK) pathway, and all of the downstream functions mediated by AMPK including increased fatty acid oxidation, enhanced glucose transport and decreased fatty acid synthesis.
A method for treating obesity, type 2 diabetes, insulin resistance, metabolic syndrome and syndromes, conditions and complications associated with any of the foregoing, comprising the step of administering to an animal in need thereof an inhibitor of AICARFT in an amount sufficient to inhibit AICARFT enzyme activity.
A method for increasing endogenous AICAR-monophosphate levels in a metabolic cell or tissue comprising the step of administering to the cell or tissue an inhibitor of AICARFT in an amount sufficient to increase AMP kinase activity.
A method for increasing the oxidation of fatty acids in a metabolic cell or tissue comprising the step of administering to the cell or tissue an inhibitor of AICARFT in an amount sufficient to inhibit AICARFT enzyme activity.
A method for increasing glucose uptake in a metabolic cell or tissue comprising the step of administering to the cell or tissue an inhibitor of AICARFT in an amount sufficient to inhibit AICARFT enzyme activity.
A method for decreasing fatty acid synthesis in a metabolic cell or tissue comprising the step of administering to the cell or tissue an inhibitor of AICARFT in an amount sufficient to inhibit AICARFT enzyme activity.
A method for inhibiting AICARFT in a metabolic cell or tissue comprising the step of administering to the cell or tissue an inhibitor of AICARFT in an amount sufficient to mimic the effect of AICAR on AMP kinase activity when administered at a lower concentration.
A method for identifying an agent useful for treating obesity, type 2 diabetes, insulin resistance, metabolic syndrome and syndromes, conditions and/or complications associated with any of the foregoing, comprising the step of screening one or more putative agents in a metabolic tissue or cell that modulate one or more of endogenous AICAR-MP levels, AMP kinase activity, fatty acid beta-oxidation, glucose uptake and fatty acid synthesis through AICARFT inhibition, wherein an agent that increases AICAR-MP levels, AMP kinase activity, fatty acid beta-oxidation or glucose uptake, or decreases fatty acid synthesis through AICARFT inhibition is identified as a useful agent.
Dependencies are inferred from the claim text.